- Home
- OPCH vs CRSP Comparison
OPCH vs CRSP Comparison
Compare OPCH & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- CRSP
- Stock Information
- Founded
- OPCH N/A
- CRSP 2013
- Country
- OPCH United States
- CRSP Switzerland
- Employees
- OPCH N/A
- CRSP N/A
- Industry
- OPCH Medical/Nursing Services
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPCH Health Care
- CRSP Health Care
- Exchange
- OPCH Nasdaq
- CRSP Nasdaq
- Market Cap
- OPCH 4.7B
- CRSP 4.9B
- IPO Year
- OPCH N/A
- CRSP 2016
- Fundamental
- Price
- OPCH $28.03
- CRSP $59.07
- Analyst Decision
- OPCH Strong Buy
- CRSP Buy
- Analyst Count
- OPCH 7
- CRSP 16
- Target Price
- OPCH $36.14
- CRSP $72.27
- AVG Volume (30 Days)
- OPCH 1.9M
- CRSP 1.9M
- Earning Date
- OPCH 10-29-2025
- CRSP 11-04-2025
- Dividend Yield
- OPCH N/A
- CRSP N/A
- EPS Growth
- OPCH 5.29
- CRSP N/A
- EPS
- OPCH 1.26
- CRSP N/A
- Revenue
- OPCH $5,374,021,000.00
- CRSP $38,050,000.00
- Revenue This Year
- OPCH $14.82
- CRSP N/A
- Revenue Next Year
- OPCH $8.49
- CRSP $348.18
- P/E Ratio
- OPCH $22.20
- CRSP N/A
- Revenue Growth
- OPCH 17.07
- CRSP N/A
- 52 Week Low
- OPCH $21.39
- CRSP $30.04
- 52 Week High
- OPCH $35.53
- CRSP $71.13
- Technical
- Relative Strength Index (RSI)
- OPCH 44.77
- CRSP 58.71
- Support Level
- OPCH $27.30
- CRSP $51.63
- Resistance Level
- OPCH $29.60
- CRSP $62.08
- Average True Range (ATR)
- OPCH 0.72
- CRSP 2.62
- MACD
- OPCH -0.06
- CRSP 0.80
- Stochastic Oscillator
- OPCH 28.40
- CRSP 73.24
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.